| Ytd | 86.84% | |
| 1y | 144.83% |
| Open | 7.53 | Prev Close | 7.60 | Low | 7.47 | High | 7.84 | Mkt Cap | 2.78B |
| Vol | 3.38M | Avg Vol | 5.03M | EPS | -1.04 | P/E | N/A | Forward P/E | -35.50 |
| Beta | 0.92 | Short Ratio | 10.36 | Inst. Own | 72.83% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 7.20 | 200-d Avg | 5.07 | 1yr Est | 13.65 |
PGEN News
Precigen (NASDAQ: PGEN - Get Free Report) and Pyxis Oncology (NASDAQ: PYXS - Get Free Report) are bo
U.S. stock futures fell; Constellation Brands dropped 5.1% despite beating estimates, while biotech,
Precigen is building momentum with Papzimeos sales growth, a European regulatory review and progress
Precigen (NASDAQ: PGEN - Get Free Report) and PTC Therapeutics (NASDAQ: PTCT - Get Free Report) are
Analysts initiated bullish coverage on TSEM, PGEN, SPTX, PDFS and CF, setting targets of $300, $12,
B. Riley Securities analyst Yuan Zhi initiates coverage on Precigen (NASDAQ:PGEN) with a Buy rati
Wall Street analysts changed outlook on top names. UBS cut Fidelity National Information target, JP
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Precigen (NASDAQ:PGEN) with a Bu
Arista Networks Inc (ANET) reported strong Q2 results, with revenue of $3.04B, up 37.7% YoY. Shares
Gainers Bluejay Diagnostics (NASDAQ:BJDX) stock moved upwards by 42.0% to $1.42 during Tuesday'
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Precigen (NASDAQ:PGEN) with a B
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Precigen (NASDAQ:PGEN) with a Bu
FDA grants orphan drug exclusivity for PAPZIMEOS for the treatment of adults with recurrent respirat
Citizens analyst Jason N. Butler maintains Precigen (NASDAQ:PGEN) with a Market Outperform and ra
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Precigen (NASDAQ:PGEN) with a Bu
Cisco Inc (NASDAQ: CSCO) beat expectations and raised guidance with $15.84B revenue and $1.06 EPS. S
Precigen (NASDAQ:PGEN) reported quarterly losses of $(0.02) per share which met the analyst consensu
Precigen Inc. (NASDAQ:PGEN), a commercial-stage biopharmaceutical company developing precision medic
The U.S. trade deficit in goods shrank to $87.3 billion in February from $88.6 billion in January, w
Precigen, Inc. (NASDAQ:PGEN) reported mixed Q4 results, with a loss of 1 cent per share beating esti
Olaplex Holdings shares surge 51% after being acquired by Henkel AG & Co. KGaA. Other big gainer
Citizens analyst Jason N. Butler maintains Precigen (NASDAQ:PGEN) with a Market Outperform and ra
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Precigen (NASDAQ:PGEN) with a Bu
Shares of Navan Inc (NASDAQ: NAVN) spiked in pre-market trading on better-than-expected Q4 results.
Precigen (NASDAQ:PGEN) reported quarterly losses of $(0.01) per share which beat the analyst consens
Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the adv
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Precigen (NASDAQ:PGEN) with a Bu
Precigen (NASDAQ:PGEN) reported quarterly losses of $(1.06) per share which missed the analyst conse
Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the advancement of innovat
The credit facility provides Precigen with up to $125 million committed across two tranches, subject
JMP Securities analyst Jason N. Butler maintains Precigen (NASDAQ:PGEN) with a Market Outperform
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Precigen (NASDAQ:PGEN) with a B
